3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Paclitaxel
291
Gemcitabine
254
Carboplatin
253
Cisplatin
250
Radiotherapy
219
Cyclophosphamide
218
Irinotecan
184
pembrolizumab
180
Docetaxel
174
Bevacizumab
166
Capecitabine
148
Nivolumab
141
Fluorouracil
132
Dexamethasone
125
Bortezomib
123
Oxaliplatin
115
Cytarabine
113
Erlotinib Hydrochloride
112
Sorafenib
110
Temozolomide
109
Doxorubicin
106
Rituximab
105
Leucovorin
105
Etoposide
105
Filgrastim
99
Everolimus
97
Lenalidomide
95
Ipilimumab
90
Pemetrexed
89
fludarabine phosphate
84
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Completed
×
pegilodecakin
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled